We’ve seen a phase 2 trial that showed excellent local control with SABR for sarcoma lung mets. In this retrospective review, 70 patients were treated with SABR for 98 lung metastases. At 2 years, local recurrence free survival was 83%. However, the main predictor of improved PFS was having controlled systemic disease. In other words, SABR shines when controlling oligometastatic disease in the lung with well controlled systemic disease. | Farooqi, Int J Radiat Oncol Biol Phys 2023
